China medtech industry Report Interpretation

Overview

This UBS China medtech earnings read-across reviews Q226 results from major global companies. It concludes that procedure-led consumables demand remained resilient and diagnostics pressure was easing, but capital equipment conditions were mixed and system placements were a notable weak point.

Core views

UBS says major global medtech companies delivered largely in-line China results in Q226, although negative surprises were present. Electrophysiology (EP) and robot-assisted surgery procedures continued to show stable volume growth. Diagnostics companies still generally reported year-on-year China sales declines, but several experienced a smaller magnitude of decline. UBS's main concern is capital equipment, where results were notably uneven; it also observes that management teams appeared less concerned than expected about upcoming China risks such as anti-corruption measures, equipment volume-based procurement (VBP), and in-vitro diagnostics (IVD) test-price reform. UBS intends to compare these views with forthcoming local-company earnings. Equipment results illustrate the divergence. Siemens Healthineers' China revenue declined 10% year-on-year in April–June 2026, reflecting difficult comparisons in Imaging and Precision Therapy and a sharp diagnostics decline caused by structural market change. It viewed the proposed capital-equipment VBP as distinct from traditional VBP and not unexpected, and expects China's imaging market eventually to recover to mid-single-digit growth. GE HealthCare reported 3.4% China revenue growth in Q226, in line with its expectations, and described equipment-VBP expansion as evolutionary rather than disruptive; nevertheless, it still assumes China revenue will decline year-on-year in 2026. Philips reported a Q226 decline in China Diagnosis & Treatment revenue and remained cautious, believing VBP could be disruptive ahead of implementation. Intuitive Surgical was the clearest system-placement negative surprise. China Da Vinci procedure growth was slightly above the global average in Q226, but the company placed only two surgical systems, versus 13 in Q225. It cited persistently challenging conditions: lower tender activity, rising local-peer competition and policy-led pricing pressure. Regarding capital-equipment VBP, Intuitive Surgical believes the government's principal aim is to make tenders more structured. In diagnostics, Roche's China diagnostics revenue improved sequentially at constant exchange rates but still fell more than 15% year-on-year in Q226, following a 14% decline in Q126. Roche continued to expect a reduced effect from China price reforms in 2026; it also reported diagnostics cost of goods sold growth of 5% year-on-year against 3% revenue growth in H126, partly attributable to the reforms. Abbott described China VBP as an ongoing challenge for Core Lab, but expected its 2026 China revenue decline to be materially smaller, at mid-single digits. Danaher's China core revenue grew at a mid-single-digit rate in Q226, supported by Biotechnology, while diagnostics improved sequentially as the largest year-on-year impact from VBP and reimbursement changes beginning in late 2024 started to pass. Danaher expects a milder China-policy headwind in H226. Consumables and procedure-linked businesses were more stable. Boston Scientific sustained double-digit China revenue growth, led mainly by interventional cardiology and EP. Johnson & Johnson's EP growth was 3.1% year-on-year, with China inventory reducing growth by 400 basis points according to the company; its Surgery growth remained pressured by China VBPs. Overall, UBS frames the sector as resilient in procedures and improving in diagnostics, but still exposed to uneven equipment demand and policy-related pricing and procurement effects.

Analysis framework

UBS compares Q226 China revenue, procedure volumes, system placements and management commentary across global medtech companies. It separates the read-across into equipment, diagnostics and consumables, then assesses how procurement, reimbursement, pricing reforms, tender activity and competition affect each segment.

Methodology notes

• OtherSupply-demand framework

  Segment-level comparison of procedure demand, equipment placements, tender activity and policy-driven pricing pressure.

  UBS uses company results to distinguish relatively stable procedure-led consumables demand from weaker and more policy-sensitive capital-equipment demand, while tracking easing diagnostics reform effects.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Siemens Healthineers

  China equipment and diagnostics read-across

  Strengths

  Expects China's imaging market to recover to mid-single-digit growth over time.

  Weaknesses

  China revenue fell 10% year-on-year in April–June 2026.

  Comparison

  Equipment results were mixed versus GE HealthCare's 3.4% China growth.

  Risks

  Structural diagnostics-market change and capital-equipment procurement reform.

• GE HealthCare

  China equipment read-across

  Strengths

  China revenue grew 3.4% year-on-year in Q226.

  Weaknesses

  The company still assumes a year-on-year China revenue decline for 2026.

  Comparison

  More resilient Q226 result than Siemens Healthineers and Philips.

  Risks

  China market dynamics have not improved significantly.

• Philips

  China equipment read-across

  Weaknesses

  China Diagnosis & Treatment revenue declined in Q226.

  Comparison

  Shares the cautious equipment outlook seen across parts of the sector.

  Risks

  VBP may be disruptive ahead of implementation.

• Intuitive Surgical

  China robot-assisted surgery read-across

  Strengths

  China Da Vinci procedure growth was slightly above the global average.

  Weaknesses

  Only two Da Vinci systems were placed in China versus 13 in Q225.

  Comparison

  System placements were a negative surprise despite resilient procedures.

  Risks

  Lower tender activity, local competition and policy-driven pricing pressure.

• Roche

  China diagnostics read-across

  Strengths

  China diagnostics revenue improved sequentially at constant exchange rates.

  Weaknesses

  Revenue still declined more than 15% year-on-year in Q226.

  Comparison

  Illustrates continuing but potentially easing diagnostics reform pressure.

  Risks

  Healthcare pricing reforms and associated cost pressure.

• Abbott

  China Core Lab diagnostics read-across

  Strengths

  Expected 2026 China revenue decline is likely to be limited to mid-single digits.

  Weaknesses

  VBP remains a lingering challenge for Core Lab.

  Comparison

  Points to a milder outlook than Roche's continued double-digit decline.

  Risks

  Ongoing VBP effects.

• Danaher

  China diagnostics and biotechnology read-across

  Strengths

  China core revenue grew at a mid-single-digit rate, supported by Biotechnology; diagnostics improved sequentially.

  Weaknesses

  Prior VBP and reimbursement changes continued to affect comparisons.

  Comparison

  Expects milder China-policy headwinds in H226.

  Risks

  China policy reform effects.

• Boston Scientific

  China consumables and procedure read-across

  Strengths

  Maintained double-digit China revenue growth, led by interventional cardiology and EP.

  Comparison

  More resilient than capital-equipment suppliers.

• Johnson & Johnson

  China EP and surgery read-across

  Strengths

  EP revenue grew 3.1% year-on-year.

  Weaknesses

  China inventory reduced EP growth by 400 basis points; Surgery remained pressured.

  Comparison

  Shows resilient EP demand but ongoing VBP pressure in Surgery.

  Risks

  Inventory effects and China VBP.

Key data

• Siemens Healthineers China revenue-10% YoY in Apr-Jun 2026Decline reflected difficult comparisons in Imaging and Precision Therapy and a sharp diagnostics fall.
• GE HealthCare China revenue+3.4% YoY in Q226In line with company expectations.
• Intuitive Surgical Da Vinci system placements in China2 systems in Q226 vs. 13 in Q225Negative surprise despite procedure growth slightly above the global average.
• Roche China diagnostics revenueMore than -15% YoY in Q226 vs. -14% in Q126Sequential constant-currency improvement did not offset continued year-on-year pressure.
• Roche diagnostics H126 growthCOGS +5% YoY; revenue +3% YoYThe company attributed part of the cost-growth gap to China pricing reform.
• Johnson & Johnson EP growth+3.1% YoYChina inventory reduced growth by 400 basis points according to the company.

Impact & implications

UBS's read-across suggests that policy reform effects on diagnostics may become less severe in H226, while equipment suppliers remain more exposed to tender activity, procurement implementation, pricing pressure and domestic competition. Procedure-led consumables appear comparatively resilient, although company-specific inventory and VBP effects remain relevant.

Risks

• Larger-than-expected price reductions and smaller-than-expected market-share gains from medical-device VBP programmes.
• Weaker-than-expected demand from equipment-renewal programmes.
• A greater-than-expected effect from the anti-corruption drive.
• Geopolitical risks affecting medical-device product supply chains.
• Slower-than-expected product R&D and technological breakthroughs.

What to watch

• Local China medtech companies' earnings commentary on policy and demand conditions.
• Implementation and market impact of capital-equipment VBP.
• China tender activity and Da Vinci system placements.
• The pace at which IVD price and reimbursement reforms ease in H226 and whether risks for 2027 emerge.